Evaxion reports EVX-01 induces strong immune responses in phase 2 melanoma trial

• Evaxion announced new Phase 2 data showing strong immune responses to personalized cancer vaccine EVX-01 in patients with advanced melanoma.
• Findings supported its AI platform’s ability to select vaccine targets likely to generate strong immune responses.
• Results will be presented November 6-7, 2026, at the Society for Immunotherapy of Cancer annual meeting in Phoenix.
• Previously presented three-year follow-up data showed sustained immune and clinical responses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611061100OMX_____CNEWS_EN_GNW1001302254_en) on November 06, 2026, and is solely responsible for the information contained therein.